Zobrazeno 1 - 10
of 91
pro vyhledávání: '"Antonella Russo, Rossi"'
Autor:
Francesco Tarantini, Cosimo Cumbo, Antonella Zagaria, Elisa Parciante, Luisa Anelli, Nicoletta Coccaro, Giuseppina Tota, Crescenzio Francesco Minervini, Immacolata Redavid, Antonella Russo Rossi, Maria Rosa Conserva, Giorgina Specchia, Pellegrino Musto, Francesco Albano
Publikováno v:
Hematology, Vol 27, Iss 1, Pp 842-846 (2022)
Objectives BCR-ABL1 and JAK2 V617F coexistence in myeloproliferative neoplasms has been described as concomitant or sequential events. Despite this, we present a unique case of chronic myeloid leukemia (CML) not referable to either of the known scena
Externí odkaz:
https://doaj.org/article/87e9516077cc43bda9053eeed6d3c343
Autor:
Massimo Breccia, Antonella Russo Rossi, Valentina Giai, Bruno Martino, Carmen Fava, Mario Annunziata, Elisabetta Abruzzese, Gianni Binotto, Claudia Baratè, Aurelio Pio Nardozza, Alessandra Misto, Paola Coco, Valeria Calafiore, Maria Cristina Carraro, Federica Cattina, Francesco Cavazzini, Maria Teresa Corsetti, Lara Crucitti, Monica Crugnola, Paolo Ditonno, Ambra DI Veroli, Anna Ermacora, Felicetto Ferrara, Angelo Genua, Antonella Gozzini, Stefana Impera, Alessandra Iurlo, Luciano Levato, Luigiana Luciano, Maria Cristina Miggiano, Marco De Gobbi, Marco Santoro, Barbara Scappini, Anna Rita Scortechini, Andrea Patriarca, Serena Rosati, Sabina Russo, Rosaria Sancetta, Grazia Sanpaolo, Teresa Maria Santeramo, Silvia Sibilla, Federica Sorà, Paolo Sportoletti, Fabio Stagno, Elena Trabacchi, Fausto Castagnetti
Publikováno v:
HemaSphere, Vol 7, p e55133e1 (2023)
Externí odkaz:
https://doaj.org/article/7ea0bb7830224451ba8d9aae8fc0796c
Autor:
Michele Malagola, Alessandra Iurlo, Elisabetta Abruzzese, Massimiliano Bonifacio, Fabio Stagno, Gianni Binotto, Mariella D’Adda, Monia Lunghi, Monica Crugnola, Maria Luisa Ferrari, Francesca Lunghi, Fausto Castagnetti, Gianantonio Rosti, Roberto M. Lemoli, Rosaria Sancetta, Maria Rosaria Coppi, Maria Teresa Corsetti, Giovanna Rege Cambrin, Atelda Romano, Mario Tiribelli, Antonella Russo Rossi, Sabina Russo, Lara Aprile, Monica Bocchia, Lisa Gandolfi, Mirko Farina, Simona Bernardi, Nicola Polverelli, Aldo M. Roccaro, Antonio De Vivo, Michele Baccarani, Domenico Russo
Publikováno v:
Cancer Medicine, Vol 10, Iss 5, Pp 1726-1737 (2021)
Abstract Background Intermittent treatment with TKIs is an option for the great majority (70%–80%) of CML patients who do not achieve a stable deep molecular response and are not eligible for treatment discontinuation. For these patients, the only
Externí odkaz:
https://doaj.org/article/b182193348604dd0987cace12205f347
Autor:
Cosimo Cumbo, Francesco Tarantini, Antonella Zagaria, Luisa Anelli, Crescenzio Francesco Minervini, Nicoletta Coccaro, Giuseppina Tota, Luciana Impera, Elisa Parciante, Maria Rosa Conserva, Immacolata Redavid, Paola Carluccio, Mario Delia, Annamaria Giordano, Maria Chiara Longo, Tommasina Perrone, Antonella Russo Rossi, Giorgina Specchia, Pellegrino Musto, Francesco Albano
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Inflammatory bowel diseases (IBDs) are a group of chronic conditions of the gastrointestinal tract in which nationwide studies have revealed a higher risk of hematological malignancies (HMs). Clonal hematopoiesis (CH) is a premalignant condition defi
Externí odkaz:
https://doaj.org/article/f839630c27d04da8aaad77d31af5a75d
Autor:
Anna Sicuranza, Ilaria Ferrigno, Elisabetta Abruzzese, Alessandra Iurlo, Sara Galimberti, Antonella Gozzini, Luigiana Luciano, Fabio Stagno, Antonella Russo Rossi, Nicola Sgherza, Daniele Cattaneo, Corrado Zuanelli Brambilla, Cristina Marzano, Carmen Fava, Olga Mulas, Emanuele Cencini, Adele Santoni, Vincenzo Sammartano, Alessandro Gozzetti, Luca Puccetti, Monica Bocchia
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Tyrosine kinase inhibitors (TKI) may offer a normal life expectancy to Chronic Myeloid Leukemia (CML) patients. However, a higher than expected incidence of arterial occlusive events (AOEs) was observed during treatment with nilotinib. We previously
Externí odkaz:
https://doaj.org/article/5ddf4f9f79054a4e8cbdd98e58692599
Autor:
Francesco Tarantini, Cosimo Cumbo, Elisa Parciante, Luisa Anelli, Antonella Zagaria, Nicoletta Coccaro, Crescenzio Francesco Minervini, Giuseppina Tota, Immacolata Redavid, Maria Rosa Conserva, Immacolata Attolico, Antonella Russo Rossi, Giorgina Specchia, Pellegrino Musto, Francesco Albano
Publikováno v:
Acta Haematologica. 146:37-43
Introduction: Interferon regulatory factor 4 (IRF4) is a transcriptional factor with a key role in the modulation of inflammation and immune surveillance. The IRF4 gene is downregulated in Philadelphia-negative myeloproliferative neoplasms, and its e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed76975bba325e96acd23921914f1a09
https://doi.org/10.1159/000527173
https://doi.org/10.1159/000527173
Autor:
Roberto Latagliata, Fabio Stagno, Mario Annunziata, Elisabetta Abruzzese, Alessandra Iurlo, Attilio Guarini, Carmen Fava, Antonella Gozzini, Massimiliano Bonifacio, Federica Sorà, Sabrina Leonetti Crescenzi, Monica Bocchia, Monica Crugnola, Fausto Castagnetti, Isabella Capodanno, Sara Galimberti, Costanzo Feo, Raffaele Porrini, Patrizia Pregno, Manuela Rizzo, Agostino Antolino, Endri Mauro, Nicola Sgherza, Luigiana Luciano, Mario Tiribelli, Antonella Russo Rossi, Malgorzata Trawinska, Paolo Vigneri, Massimo Breccia, Gianantonio Rosti, Giuliana Alimena
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 18, Iss 9, Pp 536-540 (2016)
Dasatinib (DAS) has been licensed for the frontline treatment in chronic myeloid leukemia (CML). However, very few data are available regarding its efficacy and toxicity in elderly patients with CML outside clinical trials. To address this issue, we
Externí odkaz:
https://doaj.org/article/cf326cb4083d49d69854ac476b662cf8
Autor:
Antonella Russo Rossi
Publikováno v:
Clinical Management Issues, Vol 7, Iss 1S, Pp 19-23 (2015)
We report a case of a patient with chronic myeloid leukemia diagnosed in January 2012 and treated with nilotinib 600 mg/die as first line therapy. Patient obtained a complete hematologic response (CHR) and improvement of splenomegaly in 2 weeks. In t
Externí odkaz:
https://doaj.org/article/52f4f655945c41d8a2a589216a718da9
Autor:
Antonella Russo Rossi
Publikováno v:
Clinical Management Issues, Vol 4, Iss 5S, Pp 23-27 (2015)
In this article is presented the case of a 30-year-old woman with chronic myeloid leukaemia (CML) treated with imatinib for 15 months, and then with nilotinib as second-line therapy. Two episodes of grade 3 neutropenia, the detection of the trisomy o
Externí odkaz:
https://doaj.org/article/2ca90d2219d84a0588c828ccf34fbe37
Autor:
Francesco Tarantini, Cosimo Cumbo, Antonella Zagaria, Luisa Anelli, Elisa Parciante, Immacolata Redavid, Nicoletta Coccaro, Giuseppina Tota, Maria Rosa Conserva, Crescenzio Francesco Minervini, Angela Minervini, Immacolata Attolico, Antonella Russo Rossi, Giorgina Specchia, Pellegrino Musto, Francesco Albano
Publikováno v:
Leukemia Research. 127:107023
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a37b885f40c4791f3e3f8b3a926eca19
https://doi.org/10.1016/j.leukres.2023.107023
https://doi.org/10.1016/j.leukres.2023.107023